Next Article in Journal
Pre-Emptive Drug Safety Evaluation of Iclepertin (BI-425809) Using Real-World Data and Virtual Addition of This Medication to the Actual Drug Regimen of Individuals from Large Populations
Previous Article in Journal
Reply to Sikiric et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide’s Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on “Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals 2025, 18, 185”
Previous Article in Special Issue
Safety, Tolerability, and Pharmacokinetics of Filapixant, a Highly Selective P2X3 Receptor Antagonist, in an Ascending-Single-Dose First-in-Human Study
 
 
Review

Article Versions Notes

Pharmaceuticals 2025, 18(10), 1452; https://doi.org/10.3390/ph18101452
Action Date Notes Link
article html file updated 29 September 2025 08:06 CEST Update https://www.mdpi.com/1424-8247/18/10/1452/html
article pdf uploaded. 29 September 2025 08:03 CEST Updated version of record https://www.mdpi.com/1424-8247/18/10/1452/pdf
article xml uploaded. 29 September 2025 08:03 CEST Update https://www.mdpi.com/1424-8247/18/10/1452/xml
article xml file uploaded 29 September 2025 08:03 CEST Update -
article html file updated 28 September 2025 11:00 CEST Original file -
article pdf uploaded. 28 September 2025 10:58 CEST Version of Record https://www.mdpi.com/1424-8247/18/10/1452/pdf-vor
article xml uploaded. 28 September 2025 10:58 CEST Update -
article xml file uploaded 28 September 2025 10:58 CEST Original file -
Back to TopTop